4th February 2020
NICE erenumab appeal outcome
The Migraine Trust welcomes NICE decision to look again at its erenumab rejection
The Migraine Trust is very pleased to hear that the National Institute of Health and Care Excellence (NICE) has decided to look again at its decision to reject erenumab (Aimovig).
The original decision by NICE – made in September 2019 – to reject the use of the calcitonin gene-related peptide (CGRP) drug on the NHS in England and Wales was appealed by the British Association for the Study of Headache (BASH) and the Association of British Neurologists (ABN).
The NICE appeal panel has decided that the appraisal committee unreasonably failed to consider all of the evidence about the cost-effectiveness of erenumab for patients who have failed to respond to botulinum toxin (Botox).
Evidence submitted to NICE
The Migraine Trust recently submitted evidence to NICE that shows that around 8% of chronic migraine patients fail to respond to Botox therapy.
We’ve also submitted evidence that shows that around three quarters (77%) of Botox ‘non-responders’ say that taking a CGRP has improved their quality of life.
We’ve also submitted evidence that shows that around 9% of chronic migraine patients currently receiving Botox injections have been forced to skip or delay a course of injections over the past 12 months due to access, availability, or system capacity issues.
The Migraine Trust continues to believe that chronic migraine patients across the UK should have access to CGRP drugs free on the NHS if and when they and their clinician thinks it is in their best interest to take them.
This latest announcement by NICE does not mean that its original decision to reject erenumab has been overturned. It means that the decision now returns to the appraisal committee to consider whether erenumab is a cost-effective treatment for chronic migraine patients who have tried Botox but found it didn’t work for them.
We are awaiting word from NICE about how long this new step will take and what it will involve. We will update migraine patients as soon as we know.